atopic dermatitis

News

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

Woman with vitiligo crosses her arms in front of her chest

Pfizer cues up vitiligo filing for Litfulo after phase 3 win

Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.

News

Sanofi gives up on amlitelimab in atopic dermatitis

Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.

News